Risk factors and prevention of hepatocellular carcinoma in the era of precision medicine

Naoto Fujiwara, Scott L. Friedman, Nicolas Goossens, Yujin Hoshida

Research output: Contribution to journalReview article

62 Citations (Scopus)

Abstract

Patients who develop chronic fibrotic liver disease, caused by viral or metabolic aetiologies, are at a high risk of developing hepatocellular carcinoma (HCC). Even after complete HCC tumour resection or ablation, the carcinogenic tissue microenvironment in the remnant liver can give rise to recurrent de novo HCC tumours, which progress into incurable, advanced-stage disease in most patients. Thus, early detection and prevention of HCC development is, in principle, the most impactful strategy to improve patient prognosis. However, a “one-size-fits-all” approach to HCC screening for early tumour detection, as recommended by clinical practice guidelines, is utilised in less than 20% of the target population, and the performance of screening modalities, including ultrasound and alpha-fetoprotein, is suboptimal. Furthermore, optimal screening strategies for emerging at-risk patient populations, such as those with chronic hepatitis C after viral cure, or those with non-cirrhotic, non-alcoholic fatty liver disease remain controversial. New HCC biomarkers and imaging modalities may improve the sensitivity and specificity of HCC detection. Clinical and molecular HCC risk scores will enable precise HCC risk prediction followed by tailoured HCC screening of individual patients, maximising cost-effectiveness and optimising allocation of limited medical resources. Several aetiology-specific and generic HCC chemoprevention strategies are evolving. Epidemiological and experimental studies have identified candidate chemoprevention targets and therapies, including statins, anti-diabetic drugs, and selective molecular targeted agents, although their clinical testing has been limited by the lengthy process of cancer development that requires long-term, costly studies. Individual HCC risk prediction is expected to overcome the challenge by enabling personalised chemoprevention, targeting high-risk patients for precision HCC prevention and substantially improving the dismal prognosis of HCC.

Original languageEnglish (US)
Pages (from-to)526-549
Number of pages24
JournalJournal of Hepatology
Volume68
Issue number3
DOIs
StatePublished - Mar 2018
Externally publishedYes

Fingerprint

Precision Medicine
Hepatocellular Carcinoma
Chemoprevention
Neoplasms
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Health Services Needs and Demand
alpha-Fetoproteins
Chronic Hepatitis C
Practice Guidelines
Cost-Benefit Analysis
Liver Diseases

Keywords

  • Cancer screening
  • Chemoprevention
  • Cirrhosis
  • Hepatocellular carcinoma
  • Precision medicine
  • Risk prediction

ASJC Scopus subject areas

  • Hepatology

Cite this

Risk factors and prevention of hepatocellular carcinoma in the era of precision medicine. / Fujiwara, Naoto; Friedman, Scott L.; Goossens, Nicolas; Hoshida, Yujin.

In: Journal of Hepatology, Vol. 68, No. 3, 03.2018, p. 526-549.

Research output: Contribution to journalReview article

Fujiwara, Naoto ; Friedman, Scott L. ; Goossens, Nicolas ; Hoshida, Yujin. / Risk factors and prevention of hepatocellular carcinoma in the era of precision medicine. In: Journal of Hepatology. 2018 ; Vol. 68, No. 3. pp. 526-549.
@article{71abc61cdcb8468a8bfdf2565591047a,
title = "Risk factors and prevention of hepatocellular carcinoma in the era of precision medicine",
abstract = "Patients who develop chronic fibrotic liver disease, caused by viral or metabolic aetiologies, are at a high risk of developing hepatocellular carcinoma (HCC). Even after complete HCC tumour resection or ablation, the carcinogenic tissue microenvironment in the remnant liver can give rise to recurrent de novo HCC tumours, which progress into incurable, advanced-stage disease in most patients. Thus, early detection and prevention of HCC development is, in principle, the most impactful strategy to improve patient prognosis. However, a “one-size-fits-all” approach to HCC screening for early tumour detection, as recommended by clinical practice guidelines, is utilised in less than 20{\%} of the target population, and the performance of screening modalities, including ultrasound and alpha-fetoprotein, is suboptimal. Furthermore, optimal screening strategies for emerging at-risk patient populations, such as those with chronic hepatitis C after viral cure, or those with non-cirrhotic, non-alcoholic fatty liver disease remain controversial. New HCC biomarkers and imaging modalities may improve the sensitivity and specificity of HCC detection. Clinical and molecular HCC risk scores will enable precise HCC risk prediction followed by tailoured HCC screening of individual patients, maximising cost-effectiveness and optimising allocation of limited medical resources. Several aetiology-specific and generic HCC chemoprevention strategies are evolving. Epidemiological and experimental studies have identified candidate chemoprevention targets and therapies, including statins, anti-diabetic drugs, and selective molecular targeted agents, although their clinical testing has been limited by the lengthy process of cancer development that requires long-term, costly studies. Individual HCC risk prediction is expected to overcome the challenge by enabling personalised chemoprevention, targeting high-risk patients for precision HCC prevention and substantially improving the dismal prognosis of HCC.",
keywords = "Cancer screening, Chemoprevention, Cirrhosis, Hepatocellular carcinoma, Precision medicine, Risk prediction",
author = "Naoto Fujiwara and Friedman, {Scott L.} and Nicolas Goossens and Yujin Hoshida",
year = "2018",
month = "3",
doi = "10.1016/j.jhep.2017.09.016",
language = "English (US)",
volume = "68",
pages = "526--549",
journal = "Journal of Hepatology",
issn = "0168-8278",
publisher = "Elsevier",
number = "3",

}

TY - JOUR

T1 - Risk factors and prevention of hepatocellular carcinoma in the era of precision medicine

AU - Fujiwara, Naoto

AU - Friedman, Scott L.

AU - Goossens, Nicolas

AU - Hoshida, Yujin

PY - 2018/3

Y1 - 2018/3

N2 - Patients who develop chronic fibrotic liver disease, caused by viral or metabolic aetiologies, are at a high risk of developing hepatocellular carcinoma (HCC). Even after complete HCC tumour resection or ablation, the carcinogenic tissue microenvironment in the remnant liver can give rise to recurrent de novo HCC tumours, which progress into incurable, advanced-stage disease in most patients. Thus, early detection and prevention of HCC development is, in principle, the most impactful strategy to improve patient prognosis. However, a “one-size-fits-all” approach to HCC screening for early tumour detection, as recommended by clinical practice guidelines, is utilised in less than 20% of the target population, and the performance of screening modalities, including ultrasound and alpha-fetoprotein, is suboptimal. Furthermore, optimal screening strategies for emerging at-risk patient populations, such as those with chronic hepatitis C after viral cure, or those with non-cirrhotic, non-alcoholic fatty liver disease remain controversial. New HCC biomarkers and imaging modalities may improve the sensitivity and specificity of HCC detection. Clinical and molecular HCC risk scores will enable precise HCC risk prediction followed by tailoured HCC screening of individual patients, maximising cost-effectiveness and optimising allocation of limited medical resources. Several aetiology-specific and generic HCC chemoprevention strategies are evolving. Epidemiological and experimental studies have identified candidate chemoprevention targets and therapies, including statins, anti-diabetic drugs, and selective molecular targeted agents, although their clinical testing has been limited by the lengthy process of cancer development that requires long-term, costly studies. Individual HCC risk prediction is expected to overcome the challenge by enabling personalised chemoprevention, targeting high-risk patients for precision HCC prevention and substantially improving the dismal prognosis of HCC.

AB - Patients who develop chronic fibrotic liver disease, caused by viral or metabolic aetiologies, are at a high risk of developing hepatocellular carcinoma (HCC). Even after complete HCC tumour resection or ablation, the carcinogenic tissue microenvironment in the remnant liver can give rise to recurrent de novo HCC tumours, which progress into incurable, advanced-stage disease in most patients. Thus, early detection and prevention of HCC development is, in principle, the most impactful strategy to improve patient prognosis. However, a “one-size-fits-all” approach to HCC screening for early tumour detection, as recommended by clinical practice guidelines, is utilised in less than 20% of the target population, and the performance of screening modalities, including ultrasound and alpha-fetoprotein, is suboptimal. Furthermore, optimal screening strategies for emerging at-risk patient populations, such as those with chronic hepatitis C after viral cure, or those with non-cirrhotic, non-alcoholic fatty liver disease remain controversial. New HCC biomarkers and imaging modalities may improve the sensitivity and specificity of HCC detection. Clinical and molecular HCC risk scores will enable precise HCC risk prediction followed by tailoured HCC screening of individual patients, maximising cost-effectiveness and optimising allocation of limited medical resources. Several aetiology-specific and generic HCC chemoprevention strategies are evolving. Epidemiological and experimental studies have identified candidate chemoprevention targets and therapies, including statins, anti-diabetic drugs, and selective molecular targeted agents, although their clinical testing has been limited by the lengthy process of cancer development that requires long-term, costly studies. Individual HCC risk prediction is expected to overcome the challenge by enabling personalised chemoprevention, targeting high-risk patients for precision HCC prevention and substantially improving the dismal prognosis of HCC.

KW - Cancer screening

KW - Chemoprevention

KW - Cirrhosis

KW - Hepatocellular carcinoma

KW - Precision medicine

KW - Risk prediction

UR - http://www.scopus.com/inward/record.url?scp=85035013654&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85035013654&partnerID=8YFLogxK

U2 - 10.1016/j.jhep.2017.09.016

DO - 10.1016/j.jhep.2017.09.016

M3 - Review article

C2 - 28989095

AN - SCOPUS:85035013654

VL - 68

SP - 526

EP - 549

JO - Journal of Hepatology

JF - Journal of Hepatology

SN - 0168-8278

IS - 3

ER -